Taking advantage of technology that can analyze tissue samples and measure the activity of thousands of genes at once, scientists at Wake Forest Baptist Medical Center are on a mission to better understand and treat interstitial cystitis (IC), a painful and difficult-to-diagnose bladder condition.
"We are looking for molecular biomarkers for IC, which basically means we are comparing bladder biopsy tissue from patients with suspected interstitial cystitis to patients without the disease. The goal is to identify factors that will lead to a more definitive diagnosis, and then use this information to tailor treatments to the patient," said senior author Stephen J. Walker, Ph.D., associate professor at Wake Forest Baptist's Institute for Regenerative Medicine.
The team's initial work, published online ahead of print in the Journal of Urology, found that tissue from IC patients with low bladder capacity had a significantly different gene expression profile than both IC patients with normal bladder capacity and study participants without IC. The findings suggest there may be a sub-type of IC.
"This is the first study to document functional genomic variation based solely on bladder capacity," said Robert J. Evans, M.D., a co-author and IC specialist in Wake Forest Baptist Urology. "Interstitial cystitis is notoriously difficult to diagnose. In fact, one report found that it takes the average patient eight years and seeing five doctors to be correctly diagnosed. The identification of biomarkers to improve diagnosis or treatment would be a significant breakthrough for patients and physicians."
IC, also known as bladder pain syndrome, is a condition in which the bladder lining is tender and easily irritated. Symptoms can include severe pelvic pain, urinary urgency and frequency and painful sexual intercourse. IC is often misdiagnosed as other conditions such as endometriosis, kidney stones or chronic urinary tract infections. The condition affects an estimated three to eight million women and one to four million men in the United States.
For the study, researchers analyzed bladder biopsies from 13 patients diagnosed with IC and three patients without the condition. The biopsies were sorted into three groups: low bladder capacity (less than 13 fluid ounces as tested under anesthesia); bladder capacity above 13 ounces; and non-IC patients. Using microarray analysis, which allows gene expression profiling on a "whole genome" scale, the researchers looked for similarities and differences in gene expression between groups. The analysis tells researchers which genes are turned "on" and which are turned "off."
The results showed a highly significant difference between low capacity patients and both the normal capacity and control patients. The low capacity patients had genes related to inflammation and immune signaling turned "on." The results may reflect a fundamental difference in disease processes.
"These gene expression differences may explain why clinical trials for IC are so variable in effectiveness and have a large number of non-responders," said Evans. "There may be subtypes of the disease that respond best to particular treatments."
Based on these early results, the team is conducting further research with the aim of identifying and validating a biomarker to aid in diagnosis and treatment of IC.
"Diseases are rarely seen as single entities anymore," said Walker. "Patients demonstrating a specific disease subtype may respond more quickly and or more favorably to treatments that target that specific subtype. Having the ability to identify the right treatment for the right patient is the ultimate goal."
This pilot research was supported by funds from the Department of Urology. Because of the promise of the data, the Interstitial Cystitis Association has awarded funding for further research.
Co-researchers were: Marc Colaco, M.D., David S. Koslov, M.D., Tristan Keys, M.D., Gopal H. Badlani, M.D., and Karl-Erik Andersson, M.D., Ph.D., all with Wake Forest Baptist.
Media Contacts: Karen Richardson, firstname.lastname@example.org, (336) 716-4453) or Main Number (336) 716-4587.
Wake Forest Baptist Medical Center is a nationally recognized academic medical center in Winston-Salem, N.C., with an integrated enterprise including educational and research facilities, hospitals, clinics, diagnostic centers and other primary and specialty care facilities serving 24 counties in northwest North Carolina and southwest Virginia. Its divisions are Wake Forest Baptist Health, a regional clinical system with close to 175 locations, 900 physicians and 1,000 acute care beds; Wake Forest School of Medicine, an established leader in medical education and research; and Wake Forest Innovations, which promotes the commercialization of research discoveries and operates Wake Forest Innovation Quarter, an urban research and business park specializing in biotechnology, materials science and information technology. Wake Forest Baptist clinical, research and educational programs are annually ranked among the best in the country by U.S. News & World Report.
Karen Richardson | Eurek Alert!
Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg
Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy